Why the study?
Although SMN is essential for the central nervous system, recent studies showed SMN is also required in peripheral non-neuronal cells, prompting investigation into its role in Dpp4+ skeletal muscle mesenchymal cells.
Answers are grounded in this paper and cite their sources.
Bap1-mediated SMN stabilization in Dpp4+ FAPs is crucial for maintaining the neuromuscular system, highlighting a potential cell-based therapeutic approach for neuromuscular diseases.
The survival of motor neuron (SMN) protein is a major component of the pre-mRNA splicing machinery and is required for RNA metabolism. Although SMN has been considered a fundamental gene for the central nervous system, due to its relationship with neuromuscular diseases, such as spinal muscular atrophy, recent studies have also revealed the requirement of SMN in non-neuronal cells in the peripheral regions. Here, we report that the fibro-adipogenic progenitor subpopulation expressing Dpp4 (Dpp4+ FAPs) is required for the neuromuscular system. Furthermore, we also reveal that BRCA1-associated protein-1 (Bap1) is crucial for the stabilization of SMN in FAPs by preventing its ubiquitination-dependent degradation. Inactivation of Bap1 in FAPs decreased SMN levels and accompanied degeneration of the neuromuscular junction, leading to loss of motor neurons and muscle atrophy. Overexpression of the ubiquitination-resistant SMN variant, SMNK186R, in Bap1-null FAPs completely prevented neuromuscular degeneration. In addition, transplantation of Dpp4+ FAPs, but not Dpp4- FAPs, completely rescued neuromuscular defects. Our data reveal the crucial role of Bap1-mediated SMN stabilization in Dpp4+ FAPs for the neuromuscular system and provide the possibility of cell-based therapeutics to treat neuromuscular diseases.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: